High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 1
- Quanjer PH, 1983, Bull Eur Physiopathol Respir, 19, 1
Cited by
Items 401–500 of 960
Reducing Carcinogenic Acetaldehyde Exposure in the Achlorhydric Stomach With Cysteine
Linderborg, K., Marvola, T., Marvola, M., Salaspuro, M. P., Färkkilä, M. A., & Vakevainen, S. M. (2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01368.x · Cited by 29
Measuring health-related quality of life in drug clinical trials: is it given due importance?
Miguel, R. S., López-González, A. M., Sánchez, E., Mar, J., & Hita, J. M. C. (2007) · Pharmacy World & Science · doi:10.1007/s11096-007-9152-9 · Cited by 31
Self-Eating: Friend or Foe? The Emerging Role of Autophagy in Idiopathic Pulmonary Fibrosis
Margaritopoulos, G. A., Tsitoura, E., Tzanakis, N., Spandidos, D. A., Siafakas, N. M., Sourvinos, G., & Antoniou, K. M. (2013) · BioMed Research International · doi:10.1155/2013/420497 · Cited by 29
“and mainly in those with less progressed disease [4, 64].”
BackgroundResultCarbocisteine inhibits oxidant‐induced apoptosis in cultured human airway epithelial cells
Yoshida, M., Nakayama, K., Yasuda, H., Kubo, H., Kuwano, K., Arai, H., & Yamaya, M. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01594.x · Cited by 29
Adrenic acid induces oxidative stress in hepatocytes
Zhao, J., Nishiumi, S., Tagawa, R., Yano, Y., Inoue, J., Hoshi, N., Yoshida, M., & Kodama, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.102 · Cited by 30
Idiopathic pulmonary fibrosis: an update
Dempsey, O. J., Kerr, K. M., Gomersall, L., Remmen, H., & Currie, G. P. (2006) · QJM · doi:10.1093/qjmed/hcl098 · Cited by 31
Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled
Wells, A. U. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00010006 · Cited by 27
Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis
Sari, E., He, C., & Margaroli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911443 · Cited by 29
“However, no survival benefits were observed [17].”
Redox-sensitive gene-regulatory events controlling aberrant matrix metalloproteinase-1 expression
Bartling, T. R., Subbaram, S., Clark, R. R., Chandrasekaran, A., Kar, S., & Melendez, J. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.017 · Cited by 27
Current clinical trials for the treatment of idiopathic pulmonary fibrosis
Klingsberg, R. C., Mutsaers, S. E., & Lasky, J. A. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01672.x · Cited by 27
Therapeutic advances in idiopathic pulmonary fibrosis
Fraser, E., & Hoyles, R. K. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-1-42 · Cited by 28
Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis
Fukihara, J., & Kondoh, Y. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1249854 · Cited by 27
“bined with prednisone and azathioprine was introduced for the management of IPF and became the standard of care [2].”
BackgroundLv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 27
Karimian, G., Mohammadi‐Karakani, A., Sotoudeh, M., Ghazi‐Khansari, M., Ghobadi, G., & Shakiba, B. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.10.020 · Cited by 25
Emerging drugs for idiopathic pulmonary fibrosis
Selman, M., Pardo, A., Richeldi, L., & Cerri, S. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.565049 · Cited by 29
“In addition, high-dose NAC has shown some immunemodulatory properties in a different lung disease such as cystic fibrosis [66].”
BackgroundMethodInfluentialThe evolving pharmacotherapy of pulmonary fibrosis
Lota, H., & Wells, A. U. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758250 · Cited by 25
Uno, K., Iijima, K., Koike, T., & Shimosegawa, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i23.7120 · Cited by 25
Management of idiopathic pulmonary fibrosis in France: A survey of 1244 pulmonologists
Cottin, V., Cadranel, J. L., Crestani, B., Dalphin, J., Delaval, P., Israël‐Biet, D., Kessler, R., Reynaud‐Gaubert, M., Valeyre, D., Wallaert, B., et al. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.11.017 · Cited by 30
Self-citationTargeted therapy for systemic sclerosis: how close are we?
Ramos‐Casals, M., Fonollosa‐Pla, V., Brito‐Zerón, P., & Sisó‐Almirall, A. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.48 · Cited by 27
Emerging therapeutic interventions for idiopathic pulmonary fibrosis
Chakraborty, S., Chopra, P., Ambi, S. V., Dastidar, S. G., & Ray, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.913569 · Cited by 29
N-Acetyl Cysteine Pre-treatment Attenuates Inflammatory Changes in the Warm Ischemic Murine Lung
Geudens, N., Wauwer, C. V. D., Neyrinck, A., Timmermans, L., Vanhooren, H. M., Vanaudenaerde, B. M., Verleden, G. M., Verbeken, E. K., Lerut, A., & Raemdonck, D. E. V. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.09.008 · Cited by 25
Self-citationCassidy, P. B., Liu, T., Florell, S. R., Honeggar, M., Leachman, S. A., Boucher, K. M., & Grossman, D. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0162 · Cited by 26
“NAC is FDA-approved for acetaminophen toxicity (19) and has subsequently been used to preserve lung function in patients with idiopathic pulmonary fibrosis (20) and to prevent contrast medium–induced nephropathy in patients undergoing angioplasty (21).”
BackgroundPirfenidone suppresses bleomycin‑induced pulmonary fibrosis and periostin expression in rats
Song, X., Yu, W., & Guo, F. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6378 · Cited by 31
“Patient prognosis is very poor and there are currently no pharmacologic therapies to improve the survival rate (2).”
Delayed Cardiomyopathy in Dystrophin Deficient mdx Mice Relies on Intrinsic Glutathione Resource
Khouzami, L., Bourin, M., Christov, C., Damy, T., Escoubet, B., Caramelle, P., Perier, M., Wahbi, K., Meune, C., Pavoine, C., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090479 · Cited by 27
Exercise decreases plasma antioxidant capacity and increases urinary isoprostanes of IPF patients
Jackson, R. M., Ramos, C., Gupta, C., & Gómez-Marín, O. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.07.021 · Cited by 25
Lynch, J. P., & Belperio, J. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_10 · Cited by 26
Hot off the breath: triple therapy for idiopathic pulmonary fibrosis—hear the PANTHER roar
McGrath, E. E., & Millar, A. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-201398 · Cited by 25
Chakraborty, S., Rao, S., & Tripathi, S. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110527 · Cited by 26
Network-based modeling of drug effects on disease module in systemic sclerosis
Kim, K., Moon, S., Park, K., & Tagkopoulos, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-70280-y · Cited by 25
Khor, Y. H., Schulte, M., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M. R. J., Ryerson, C. J., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.02163-2022 · Cited by 25
Stephen, M. J., Emami, K., Woodburn, J. M., Chia, E., Kadlecek, S. J., Zhu, J., Pickup, S., Ishii, M., Rizi, R. R., & Rossman, M. D. (2010) · Academic Radiology · doi:10.1016/j.acra.2010.06.019 · Cited by 26
Antoniou, K. M., Margaritopoulos, G. A., Proklou, Α., Karagiannis, K., Lasithiotaki, I., Soufla, G., Kastrinaki, M.-C., Spandidos, D. A., Papadaki, H. Α., & Siafakas, N. M. (2012) · Journal of Inflammation · doi:10.1186/1476-9255-9-27 · Cited by 24
“Consequently and despite recent advances [3-5], there is no effective treatment currently available which can lengthen patient ’ s survival other than lung transplantation.”
Interstitial Lung Damage Due to Cocaine Abuse: Pathogenesis, Pharmacogenomics and Therapy
Drent, M., Wijnen, P. A. H. M., & Bast, A. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988901 · Cited by 24
“Well over 100 different types of ILD have been identified on the basis of clinical presentation, causes, radiographic findings, and histopathologic examination [3-5].”
BackgroundGuidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.06.003 · Cited by 45
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis
Richeldi, L. (2012) · European Respiratory Review · doi:10.1183/09059180.00000912 · Cited by 26
Rosato, E., ROSSI, C., Molinaro, I., Giovannetti, A., Pisarri, S., & Salsano, F. (2011) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201102400319 · Cited by 24
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis
Hart, S. P., Trawinska, M., & Rupesinghe, R. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81144 · Cited by 27
Esalatmanesh, K., Jamali, A., Esalatmanesh, R., Soleimani, Z., Khabbazi, A., & Mahdavi, A. M. (2022) · Amino Acids · doi:10.1007/s00726-022-03134-8 · Cited by 24
N-Acetyl Cysteine Attenuates the Inflammatory Response in Warm Ischemic Pig Lungs
Geudens, N., Wuyts, W. A., Rega, F., Vanaudenaerde, B. M., Neyrinck, A., Verleden, G. M., Lerut, A., & Raemdonck, D. E. V. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2007.05.018 · Cited by 26
“NAC is widely used in clinical practice in a variety of diseases, including paracetamol intoxication, pulmonary oxygen toxicity, pulmonary fibrosis, and human immunodeficiency virus infection [15, 16].”
BackgroundUpdate in Diffuse Parenchymal Lung Disease 2006
Wells, A. U., & Hogaboam, C. M. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-052up · Cited by 25
Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches
Raghu, G. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00086606 · Cited by 28
“In fact, this new awareness of the lack of significant progression in the placebo group observed over a period of 48–72 weeks in clinical trials using IFN-c [17, 24], and in the IFIGENIA study [ 9 ], is somewhat reassuring.”
BackgroundResultInfluentialIdiopathic pulmonary fibrosis: Treatment update
O’Connell, O. J., Kennedy, M. P., & Henry, M. T. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0066-5 · Cited by 26
Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012
Raghu, G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61256-2 · Cited by 24
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Albera, C. (2011) · European Respiratory Review · doi:10.1183/09059180.00001711 · Cited by 23
Chung, M. P. (2011) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2011.71.3.163 · Cited by 23
Kokosi, M. A., Margaritopoulos, G. A., & Wells, A. U. (2018) · European Respiratory Review · doi:10.1183/16000617.0117-2017 · Cited by 27
Grgic, A., Lausberg, H., Heinrich, M. C., Koenig, J., Uder, M., Sybrecht, G. W., & Wilkens, H. (2007) · Respiration · doi:10.1159/000108440 · Cited by 24
Proteomic approaches for studying human parenchymal lung diseases
Kinnula, V. L., Ishikawa, N., Bergmann, U., & Ohlmeier, S. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.80 · Cited by 25
New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?
Wijsenbeek, M. S., van Manen, M. J. G., & Bonella, F. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000294 · Cited by 24
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.018 · Cited by 25
“L’essai Ifigenia, un ECR publié en 2005 [114], avait suggéré un bénéfice fonctionnel respiratoire associé à l’administration de la N-acétylcystéine (NAC) à posologie antioxydante (1,8 g/j) chez les patients atteints de FPI et recevant, par ailleurs, une association de prednisone et d’azathioprine.”
BackgroundSelf-citationSasaki, J., Matsushima, A., Ikeda, H., Inoue, Y., Katahira, J., Kishibe, M., Kimura, C., Sato, Y., Takuma, K., Tanaka, K., et al. (2022) · Acute Medicine & Surgery · doi:10.1002/ams2.739 · Cited by 31
Singh, S., & Wairkar, S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123322 · Cited by 22
Advances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 23
“The authors concluded that adding NAC to the standard prednisolone and azathioprine (Imuran) therapy had better preserved vital capacity and DLCO (IFIGENIA).”
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J. C., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2023) · Pneumologie · doi:10.1055/a-1983-6796 · Cited by 26
“Seit den initialen Studien zur Wirkung von N-Acetylcystein in Kombination mit Azathioprin und Kortison sowie als Monotherapie bei der IPF [83, 84], in denen keine überzeugende Wirkung von N-Acetylcystein auf die FVC gezeigt werden konnte, haben weitere Studien die Wirkung von N-Acetylcystein bei der IPF untersucht.”
BackgroundSelf-citationYasuoka, H., Garrett, S. M., Nguyen, X.-X., Artlett, C. M., & Feghali‐Bostwick, C. A. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00106.2018 · Cited by 21
Nelkine, L., Vrolijk, M. F., Drent, M., & Bast, A. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000684 · Cited by 23
“In-vivo studies have demonstrated the effectiveness of the antioxidant drug Nacetylcysteine (NAC) in preserving vital functions of the lung in IPF patients, when used together with standard treatment [73].”
BackgroundManagement of dyspnea in interstitial lung disease
Ryerson, C. J., Collard, H. R., & Pantilat, S. Z. (2010) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283392b51 · Cited by 23
Current and emerging drugs for idiopathic pulmonary fibrosis
Gharaee‐Kermani, M., Hu, B., Thannickal, V. J., Phan, S. H., & Gyetko, M. R. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.4.627 · Cited by 22
“A Phase III multicenter, randomized, double-blind, placebo-controlled 1 trial (IFIGENIA [Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual]) was designed to examine the efficacy of NAC in IPF [181] .”
BackgroundModulatory effects ofN-acetyl-l-cysteine on human eosinophil apoptosis
Martínez‐Losa, M., Cortijo, J., Juan, G., Ramón, M., Sanz, M., & Morcillo, E. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00073706 · Cited by 21
“NAC has proved beneficial in pulmonary diseases linked to oxidative stress [ 8 ].”
Pirfenidone for the treatment of idiopathic pulmonary fibrosis
Poletti, V. E., Ravaglia, C., & Tomassetti, S. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2014.915750 · Cited by 21
Redlarski, G., & Jaworski, J. A. (2013) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2013.07.003 · Cited by 20
“0 _ VaoðτÞdτ ð7Þ On the basis of [2,6,17,26,36,37,40,41–43] and simulationbased research by the use of the model presented (Fig.”
BackgroundTreatment strategies for idiopathic interstitial pneumonias
Wells, A. U., Kokosi, M. A., & Karagiannis, K. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000085 · Cited by 23
Therapeutic options for systemic sclerosis related interstitial lung diseases
Mouthon, L., BEREZNE, A., Guillevin, L., & Valeyre, D. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.03.018 · Cited by 22
Song, X., Shi, Y., You, J., Wang, Z., Xie, L., Zhang, C., & Xiong, J. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1640747 · Cited by 24
“…anti-fibrotic agents were reported to partially relieve symptoms and detain fibrosis progression, currently no pharmaceutical is clinically available to resolve established fibrotic nodules and completely cure fibrosis (Iyer et al. 1998; Demedts et al. 2005; Choe et al. 2010; Pini et al. 2010).”
BackgroundShariati, M., Shahrzad, E., NAİMİ, S., & Edalatmanesh, M. A. (2020) · Advances in Human Biology · doi:10.4103/aihb.aihb_65_19 · Cited by 20
Idiopathic pulmonary fibrosis.
Balamugesh, T., & Behera, D. (2007) · PubMed · Cited by 20
Inhibitory effects ofN‐acetylcysteine on the functional responses of human eosinophilsin vitro
Martínez‐Losa, M., Cortijo, J., Juan, G., O’Connor, J., Sanz, M., Santangelo, F., & Morcillo, E. J. (2007) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02694.x · Cited by 20
Long-Term Efficacy of Inhaled N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis
Bando, M., Hosono, T., Mato, N., Nakaya, T., Yamasawa, H., Ohno, S., & Sugiyama, Y. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.4011 · Cited by 20
“According to previous randomized control studies using IFN-γ, pirfenidone, NAC, etanercept and bosentan (3-5, 12, 13), the yearly ΔFVC was presumed to be 160200 mL in the placebo group.”
BackgroundMethodResultInfluentialChiang, C., Chuang, C., Liu, S.-L., Chian, C., Zhang, H., & Ryu, J. H. (2012) · Injury · doi:10.1016/j.injury.2011.12.026 · Cited by 20
The European IPF Network: towards better care for a dreadful disease
Günther, A. (2011) · European Respiratory Journal · doi:10.1183/09031936.00012111 · Cited by 23
Hammond, M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., Stirling, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2453-6 · Cited by 20
“Immunosuppressive therapy is no longer advised [4], and the initial claims of the beneficial effects of N-acetyl cysteine [5] have not been substantiated when given as monotherapy [6].”
BackgroundIron overload and mitochondrial dysfunction orchestrate pulmonary fibrosis
Li, S., Zhang, H., Chang, J., Li, D., & Cao, P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174613 · Cited by 30
Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside
Amratia, D., Viola, H., & Ioachimescu, O. C. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002161 · Cited by 21
Corrêa, M. J. U., Mariz, H. D. A., Andrade, L. E. C., & Kayser, C. (2014) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2014.07.001 · Cited by 21
Recommendations on treatment for IPF
Behr, J., & Richeldi, L. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-s1-s6 · Cited by 21
“[4] The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) [8] study investigated triple combination therapy with highdose NAC (600 mg TID) versus placebo on a “standard” background therapy of prednisone and azathioprine in all IPF patients enrolled.”
MethodSelf-citationBmi1 plays an important role in dentin and mandible homeostasis by maintaining redox balance.
Yin, Y., Xue, X., Wang, Q., Chen, N., & Miao, D. (2016) · PubMed Central · Cited by 19
R1R2 peptide ameliorates pulmonary fibrosis in mice through fibrocyte migration and differentiation
Chiang, H., Chu, P., & Lee, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185811 · Cited by 19
He, J., Chen, W., Deng, S., Xie, L., Feng, J., Geng, J., Jiang, D., Dai, H., & Wang, C. (2017) · RSC Advances · doi:10.1039/c7ra06752f · Cited by 20
Idiopathic pulmonary fibrosis and pirfenidone
Collard, H. R. (2010) · European Respiratory Journal · doi:10.1183/09031936.00006610 · Cited by 19
Cordeiro, C. R., Campos, P., Carvalho, L., Borba, A., Clemente, S., Freitas, S., Furtado, S. T., Jesus, J. M., Leal, C., Marqués, J., et al. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2017.05.005 · Cited by 23
Sio, T. T. W., Blanchard, M. J., Novotny, P. J., Patel, S. H., Rwigema, J.-C. M., Pederson, L., McGee, L. A., Gamez, M. E., Seeger, G. R., Martenson, J. A., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.031 · Cited by 19
Spagnolo, P. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_11 · Cited by 18
N‐acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis
Guibas, G. V., Spandou, E., Meditskou, S., Vyzantiadis, T., Priftis, K. Ν., & Anogianakis, G. (2013) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21145 · Cited by 18
Intraductal papillary mucinous neoplasm of the bile duct with gastric and duodenal fistulas
Hong, M. Y. (2014) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v6.i7.328 · Cited by 18
Atteinte pulmonaire au cours des polymyosites et des dermatomyosites
Marié, I., & Dominique, S. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74663-2 · Cited by 18
Bakker, J. A., Drent, M., & Bierau, J. (2007) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328273bc18 · Cited by 19
New pharmacological strategies for the treatment of pulmonary fibrosis
Gogali, A., & Wells, A. U. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379454 · Cited by 19
“Thus, the rapidity of disease progression was curtailed by 70% when anti-oxidant therapy was added to ‘best current treatment’ [Demedts et al. 2005].”
BackgroundResultEmerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“This study found that among IPF patients on the standard therapy of the time (prednisone and azathioprine), the addition of high-dose acetylcysteine pre-served vital capacity (VC) and carbon monoxide diffusion capacity (DLCO) compared to placebo [62].”
Aronson, K. I., & Suzuki, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.745908 · Cited by 20
Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Covvey, J. R., & Mancl, E. E. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014551015 · Cited by 20
“Exclusion criteria included contraindication, intolerance to or previous treatment with the proposed therapies, and comorbid diseases that would interfere with the IPF diagnosis.(20) Patients were randomized 1:1 to NAC or placebo (plus background prednisone and azathioprine) and the primary end point was absolute chan…”
BackgroundMethodInfluentialAntioxidants in respiratory diseases: Basic science research and therapeutic alternatives
Alvarado, A., & Arce, I. (2016) · Clinical Research and Trials · doi:10.15761/crt.1000163 · Cited by 21
“In IFIGENIA study, researchers found that a regimen of three drugs (prednisone, azathioprine and acetylcysteine) preserved the better lung function than the two-drug regimen (azathioprine more prednisone) in IPF [126].”
BackgroundEffect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis
Τzouvelekis, Α., Bouros, E., Oikonomou, A., Ntolios, P., Zacharis, G., Kolios, G. C., & Bouros, D. (2011) · Pulmonary Medicine · doi:10.1155/2011/849035 · Cited by 18
“The pharmacological treatment that is currently available for IPF is clearly inadequate [8, 19–25].”
BackgroundRedox Imbalance and Lung Fibrosis
Kinnula, V. L. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1912 · Cited by 19
“It is possible that antioxidant strategies (NAC) may have importance in human IPF, as suggested by the IFIGENIA trial in human IPF (10).”
Sprenger, L., Goldmann, T., Vollmer, E., Steffen, A., Wollenberg, B., Zabel, P., & Hauber, H. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.11.003 · Cited by 17
Baroke, E., Gauldie, J., & Kolb, M. R. J. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2013.838015 · Cited by 18
Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis
Leuchte, H. H., Mernitz, P., Baezner, C. J., Baumgartner, R., von Wulffen, W., Neurohr, C., & Behr, J. (2015) · Respiration · doi:10.1159/000441302 · Cited by 17
Self-citationUpdate in Diffuse Parenchymal Lung Diseases 2005
Martínez, F. J., & Keane, M. P. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2601011 · Cited by 18
“The recently published European multicenter study of NAC in IPF described above lends further support to this concept of oxidative stress ( 29 ).”
BackgroundMethodInfluentialFunction of the Airway Epithelium in Asthma
Hallstrand, T. S., Woodruff, P. G., Holgate, S. T., & Knight, D. A. (2012) · Journal of Allergy · doi:10.1155/2012/160586 · Cited by 19
Raghu, G. (2009) · CHEST Journal · doi:10.1378/chest.09-0848 · Cited by 18
Beyond TGFβ – Novel ways to target airway and parenchymal fibrosis
Boorsma, C. E., Dekkers, B. G. J., van Dijk, E. M., Kumawat, K., Richardson, J., Burgess, J. K., & John, A. E. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.08.009 · Cited by 18
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.